A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jill Goslinga
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jill Goslinga
Assistant Professor, Neurology, School of Medicine. Authored (or co-authored) 5 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT06643481
- Phase
- Phase 2 Amyotropic Lateral Sclerosis (ALS) Research Study
- Study Type
- Interventional
- Participants
- Expecting 225 study participants
- Last Updated